A PHASE 1B, OPEN-LABEL, MULTICENTER DOSE ESCALATION STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF XmAb24306 IN COMBINATION WITH CEVOSTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

  • Spencer, Andrew (Primary Chief Investigator (PCI))
  • Malherbe, Maturos (Project Manager)

Project: Research

Project Details

StatusFinished
Effective start/end date7/02/237/02/25

Keywords

  • clinical trial
  • multiple myeloma
  • Relapsed or Refractory Multiple Myeloma
  • Haematological tumours